Research and Markets: Investigation Report on China's Idarubicin Market, 2010-2019

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/vcw3st/investigation) has announced the addition of the "Investigation Report on China's Idarubicin Market, 2010-2019" report to their offering.

Developed by Italian Arca- mone, idarubicin is an analog of daunorubicin with higher fat solubility. Its main metabolite works by preventing DNA unwinding. In preliminary studies, idarubicin turns out to be more effective and less toxic than DNR and DXR in treating L1210 leukemia, P338 leukemia and Gross leukemia. Since 1988, Japan has conducted clinical research on acute leukemia.

As an anti-mitosiss agent, idarubicin is used in the first line treatment fir acute nonlymphoblastic leukemia (ANLL) relapse remission and the second line treatment of acute lymphoblastic leukemia (ALL).

According to this market survey, idarubicin enjoys an increasing demand in China with sales value rising from about CNY 14 million in 2005 to over CNY 80 million in 2014 and CAGR during the period of 2010-2014 reaching 22%. And Pfizer Hisun Pharmaceutical Co., Ltd, Pharmacia & Upjohn (IT), Pharmacia & Upjohn (Suzhou) Pharmaceutical Co., Ltd, Pfizer Inc. (IT) and Nerviano Medical Science S.r.l. (IT) occupy the market, among which Pfizer Hisun Pharmaceutical Co., Ltd had the largest market share of over 40% for sales value in 2014.

Research has shown that autologus hematopoietic stem cell transplantation (HSCT) is an effective way to treat ANLL. As idarubicin is included in autologus HSCT, its future demand is expected to be great.

Key Topics Covered:

1 Related Concepts of Idarubicin

2 Market Profile of Idarubicin in China

3 Survey on Idarubicin Sales in China, 2010-2014

4 Survey on Market Share of Major Idarubicin Manufacturers in China, 2010-2014

5 Survey on Dosage Forms of Idarubicin in China, 2010-2014

6 Reference Price of Idarubicin in Chinese Hospitals in 2014

7 Major Manufacturers of Idarubicin in Chinese Market, 2010-2014

8 Market Outlook of Idarubicin in China, 2015-2019

Companies Mentioned

- Nerviano Medical Science S.r.l.

- Pfizer Hisun Pharmaceutical Co., Ltd

- Pfizer Inc.

- Pharmacia & Upjohn

For more information visit http://www.researchandmarkets.com/research/vcw3st/investigation

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals